Jørgensen, Trine N.Alfaro, JenniferEnriquez, Hilda L.Jiang, ChaoLoo, William M.Atencio, StephanieGubbels Bupp, Melanie R.Mailloux, Christina M.Metzger, TroyFlannery, ShannonRozzo, Stephen J.Kotzin, Brian L.Rosemblatt, Mario*Bono, María RosaErickson, Loren D.2025-05-162025-05-162025-01Journal of Immunology. Volume 184, Issue 2, Pages 775 - 786. 15 January 20101550-6606https://repositorio.unab.cl/handle/ria/64716Indexación: ScopusAutoantibodies are of central importance in the pathogenesis of Ab-mediated autoimmune disorders. The murine lupus susceptibility locus Nba2 on chromosome 1 and the syntenic human locus are associated with a loss of immune tolerance that leads to antinuclear Ab production. To identify gene intervals within Nba2 that control the development of autoantibody-producing B cells and to determine the cellular components through which Nba2 genes accomplish this, we generated congenic mice expressing various Nba2 intervals where genes for the FcγR, SLAM, and IFN-inducible families are encoded. Analysis of congenic strains demonstrated that the FcγR and SLAM intervals independently controlled the severity of autoantibody production and renal disease, yet are both required for lupus susceptibility. Deregulated homeostasis of terminally differentiated B cells was found to be controlled by the FcγR interval where FcγRIIb-mediated apoptosis of germinal center B cells and plasma cells was impaired. Increased numbers of activated plasmacytoid dendritic cells that were distinctly CD19+ and promoted plasma cell differentiation via the proinflammatory cytokines IL-10 and IFNα were linked to the SLAM interval. These findings suggest that SLAM and FcγR intervals act cooperatively to influence the clinical course of disease through supporting the differentiation and survival of autoantibody-producing cells. Copyright © 2010 by The American Association of Immunologists, Inc.enAnimalsAntigensMurine LupusApoptosisAutoantibodiesKidney DiseasesGenetic Predisposition to DiseaseLupus ErythematosusSystemic; MiceCongenicPlasma CellsArtículo10.4049/jimmunol.0901322Fondecyt Grant 1060253 to M. R.Fondecyt Grant 1060834 and PFB 16 (Chile) to M.R.B.M